Cantor Fitzgerald analyst William Tanner initiated Vital Therapeutics with an Overweight rating and $18 price target. In a research note to investors, Tanner says he believes the ongoing VTL-308 Phase trial of the extracorporeal liver assist device in patients with several alcoholic hepatitis has been de-risked through incorporation of learnings from the previous VTI-208 trial, adding that he believes commercialization requirements are of a scale that Vital could undertake without a partner, if approved. Additionally, Tanner contends that pricing corresponding with the unmet medical need and clinical sequelae of untrated sAH could create significant value for investors.